Gaithersburg Vaccine Development Company Testing Candidate for COVID-19

A vaccine development company headquartered in Gaithersburg is starting clinical trials for a potential COVID-19 vaccine. 

Novavax will administer the trials for vaccine candidate NVX‑CoV2373 in two phases, a statement from the company says. Phase 1 will test 131 people in Australia for immune response and safety. Results are expected in July.

“Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID‑19 pandemic,” said President and CEO of Novavax Stanley Erck.

Phase 2 is planned to expand to more countries and test for immunity, safety and virus decline. 

On April 8, Novavax announced that it had identified NVX‑CoV2373 as a potential vaccine for COVID-19. It was effective in animal studies, according to President of Research and Development at Novavax Dr. Gregory Glenn.

Like this post? Sign up for our Daily Update here.
Maryam Shahzad

About Maryam Shahzad

Maryam is a reporter with Montgomery Community Media. She graduated from the University of Maryland in December with a bachelor's degree in broadcast journalism. Previously, she was an intern with MCM. Maryam loves visual media and always says the movie is better than the book. She can be reached at mshahzad@mymcmedia.org or on Twitter @maryam_mcm.

Comments

| Comments are closed.

Engage us on Facebook

Follow us on Twitter